Ubs Group Ag Nex Immune, Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.3 - $0.6 $4,971 - $9,943	-16,573 Reduced 99.71%	49 $0
Q4 2022 Feb 08, 2023	BUY	$0.21 - $18.5 $419 - $36,963	1,998 Added 13.66%	16,622 $3,000
Q3 2022 Nov 10, 2022	BUY	$0.6 - $17.5 $7,245 - $211,312	12,075 Added 473.72%	14,624 $8,000
Q2 2022 Aug 10, 2022	BUY	$1.61 - $4.68 $2,112 - $6,140	1,312 Added 106.06%	2,549 $4,000
Q1 2022 May 16, 2022	SELL	$1.79 - $4.65 $7,942 - $20,632	-4,437 Reduced 78.2%	1,237 $5,000
Q4 2021 Feb 14, 2022	BUY	$4.11 - $15.13 $23,320 - $85,847	5,674 New	5,674 $26,000
Q3 2021 Nov 15, 2021	SELL	$10.32 - $16.9 $11,145 - $18,252	-1,080 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$14.98 - $23.89 $12,028 - $19,183	-803 Reduced 42.64%	1,080 $18,000
Q1 2021 May 12, 2021	BUY	$17.95 - $25.91 $33,799 - $48,788	1,883 New	1,883 $36,000

Ticker NEXI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,155,600
Market Cap $6.04M
Description
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's pr...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.